Clinical Outcomes of Radiation Therapy for Brain Stem Glioma

IF 6.5 1区 医学 Q1 ONCOLOGY International Journal of Radiation Oncology Biology Physics Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1016/j.ijrobp.2024.11.059
K. Pyone , T. Tun , L. Myint , T. Hnin , A. Khaing
{"title":"Clinical Outcomes of Radiation Therapy for Brain Stem Glioma","authors":"K. Pyone ,&nbsp;T. Tun ,&nbsp;L. Myint ,&nbsp;T. Hnin ,&nbsp;A. Khaing","doi":"10.1016/j.ijrobp.2024.11.059","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Brain Stem Gliomas are up to 20% of all brain tumors in children and unusual in adults. Radiotherapy is mainstay of treatment. Surgery for brain stem glioma is difficult because of anatomical location. This study was performed to evaluate the clinical outcomes of radiotherapy in brain stem glioma.</div></div><div><h3>Methods</h3><div>Retrospective analysis of brain stem glioma patients treated with radiation therapy (54 Gy/ 30 fractions of IMRT or 3D CRT) with or without surgery or chemotherapy or other agents in Yangon General Hospital, Myanmar.</div></div><div><h3>Results</h3><div>Twenty-four patients (median age 11.8 years) were treated between 2016 and 2020. Male to female ratio was 2:3. Surgical approach (Biopsy and partial removal) was done in 16 patients. Histology revealed that anaplastic ependymoma in 2 patients, low-grade astrocytoma in 2 patients, anaplastic astrocytoma in 8 patients, glioblastoma in 4 patients and remaining 8 patients had no histological diagnosis. Radiotherapy (dose-54Gy/ 30 fractions) was given with the technique of IMRT or 3D CRT. At the time of follow-up, 8 patients had local recurrence, 10 patients died of due to disease and recurrence, 14 patients were alive. Among alive patients, 2 patients were treated with chemotherapy and 12 patients with temozolomide for 12 cycles. Patients who received temozolomide got improvement in performance status and reduced clinical symptoms; among them, 6 patients had more than 50% objective tumor response in radiological findings for follow-up 3-6 months after radiotherapy. The 3-years overall survival (OS) rate was 58.3% and 3 years Event-free Survival (EFS) rate was 50%. The medium survival time was 14 months. There is no Grade 3 or greater acute and late toxicities.</div></div><div><h3>Conclusion</h3><div>As the LMIC country with limited resources, our results of radiotherapy followed by temozolomide in brain stem gliomas have optimal outcomes. However, prospective studies of this select group of patients with larger number and longer follow-up is required.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Pages e16-e17"},"PeriodicalIF":6.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624036332","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Brain Stem Gliomas are up to 20% of all brain tumors in children and unusual in adults. Radiotherapy is mainstay of treatment. Surgery for brain stem glioma is difficult because of anatomical location. This study was performed to evaluate the clinical outcomes of radiotherapy in brain stem glioma.

Methods

Retrospective analysis of brain stem glioma patients treated with radiation therapy (54 Gy/ 30 fractions of IMRT or 3D CRT) with or without surgery or chemotherapy or other agents in Yangon General Hospital, Myanmar.

Results

Twenty-four patients (median age 11.8 years) were treated between 2016 and 2020. Male to female ratio was 2:3. Surgical approach (Biopsy and partial removal) was done in 16 patients. Histology revealed that anaplastic ependymoma in 2 patients, low-grade astrocytoma in 2 patients, anaplastic astrocytoma in 8 patients, glioblastoma in 4 patients and remaining 8 patients had no histological diagnosis. Radiotherapy (dose-54Gy/ 30 fractions) was given with the technique of IMRT or 3D CRT. At the time of follow-up, 8 patients had local recurrence, 10 patients died of due to disease and recurrence, 14 patients were alive. Among alive patients, 2 patients were treated with chemotherapy and 12 patients with temozolomide for 12 cycles. Patients who received temozolomide got improvement in performance status and reduced clinical symptoms; among them, 6 patients had more than 50% objective tumor response in radiological findings for follow-up 3-6 months after radiotherapy. The 3-years overall survival (OS) rate was 58.3% and 3 years Event-free Survival (EFS) rate was 50%. The medium survival time was 14 months. There is no Grade 3 or greater acute and late toxicities.

Conclusion

As the LMIC country with limited resources, our results of radiotherapy followed by temozolomide in brain stem gliomas have optimal outcomes. However, prospective studies of this select group of patients with larger number and longer follow-up is required.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脑干胶质瘤放射治疗的临床效果
目的脑干胶质瘤在儿童脑肿瘤中占比高达20%,在成人中并不常见。放射治疗是主要的治疗方法。由于脑干胶质瘤的解剖位置,手术治疗困难。本研究旨在评估脑干胶质瘤放疗的临床效果。方法回顾性分析在缅甸仰光总医院接受放射治疗(54 Gy/ 30分IMRT或3D CRT)的脑干胶质瘤患者,伴或不伴手术或化疗或其他药物。结果2016 - 2020年共收治24例患者,中位年龄11.8岁。男女比例为2:3。手术入路(活检和部分切除)16例。组织学显示间变性室管膜瘤2例,低度星形细胞瘤2例,间变性星形细胞瘤8例,胶质母细胞瘤4例,其余8例未见组织学诊断。放疗(剂量54gy / 30分)采用IMRT或3D CRT技术。随访时局部复发8例,因病复发死亡10例,存活14例。在存活患者中,2例患者接受化疗,12例患者接受替莫唑胺治疗,疗程为12个周期。替莫唑胺组患者运动状态改善,临床症状减轻;其中6例患者放疗后随访3 ~ 6个月,影像学表现客观肿瘤反应大于50%。3年总生存率(OS)为58.3%,3年无事件生存率(EFS)为50%。中位生存期为14个月。没有3级或以上的急性和晚期毒性。结论我国作为资源有限的中低收入国家,放疗加替莫唑胺治疗脑干胶质瘤疗效最佳。然而,需要对这组患者进行更大数量和更长时间随访的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
Radiation-Induced Acute Cardiac Injury in Patients With Left-Sided Breast Cancer: A Cardiac Magnetic Resonance Study on the Dose-Response Relation. Pretreatment Radiation Esophagitis Prediction using Quantum Machine Learning in Esophageal Cancer Patients. Multi-lead monitoring to deduce translations and rotations of the heart through respiration and its geometric implications for motion management in cardiac radioablation. The Comparative Toxicity of Focal Ablation Versus Intensity Modulated Radiation Therapy for Prostate Cancer FLASH Radiation Therapy Using High-Energy X-Rays: Validation of the Flash Effect Triggered by a Compact Device
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1